首页> 美国卫生研究院文献>Cancers >Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance Dormancy and Relapse: New Challenges and Therapeutic Opportunities
【2h】

Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance Dormancy and Relapse: New Challenges and Therapeutic Opportunities

机译:乳腺癌干细胞作为肿瘤化学抗性休眠和复发的驱动器:新的挑战和治疗机会

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer is the most frequent cancer among women worldwide. Therapeutic strategies to prevent or treat metastatic disease are still inadequate although great progress has been made in treating early-stage breast cancer. Cancer stem-like cells (CSCs) that are endowed with high plasticity and self-renewal properties have been shown to play a key role in breast cancer development, progression, and metastasis. A subpopulation of CSCs that combines tumor-initiating capacity and a dormant/quiescent/slow cycling status is present throughout the clinical history of breast cancer patients. Dormant/quiescent/slow cycling CSCs are a key component of tumor heterogeneity and they are responsible for chemoresistance, tumor migration, and metastatic dormancy, defined as the ability of CSCs to survive in target organs and generate metastasis up to two decades after diagnosis. Understanding the strategies that are used by CSCs to resist conventional and targeted therapies, to interact with their niche, to escape immune surveillance, and finally to awaken from dormancy is of key importance to prevent and treat metastatic cancer. This review summarizes the current understanding of mechanisms involved in CSCs chemoresistance, dissemination, and metastasis in breast cancer, with a particular focus on dormant cells. Finally, we discuss how advancements in the detection, molecular understanding, and targeting of dormant CSCs will likely open new therapeutic avenues for breast cancer treatment.
机译:乳腺癌是全世界女性中最常见的癌症。尽管已经在治疗早期乳腺癌方面取得了很大进展,但是预防或治疗转移性疾病的治疗策略仍然不足。具有高可塑性和自我更新特性的癌干样细胞(CSC)已显示在乳腺癌的发生,发展和转移中起关键作用。在乳腺癌患者的整个临床历史中,都存在结合了肿瘤起始能力和休眠/静止/缓慢循环状态的CSC亚群。休眠/静态/慢循环CSC是肿瘤异质性的关键组成部分,它们负责化学抗性,肿瘤迁移和转移性休眠,定义为CSC在目标器官中存活并在诊断后长达二十年的转移能力。理解CSC用来抵抗常规疗法和靶向疗法,与其利基相互作用,逃避免疫监视并最终从休眠状态唤醒的策略,对于预防和治疗转移性癌症至关重要。这篇综述总结了目前对乳腺癌中CSCs的化学抗性,扩散和转移所涉及的机制的理解,特别是针对休眠细胞。最后,我们讨论了在休眠CSC的检测,分子理解和靶向方面的进展如何为乳腺癌治疗开辟新的治疗途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号